Supplier News: Xellia, SK pharmteco, Roquette & More
The latest from CDMOs, CMOs, and suppliers featuring Xellia Pharmaceuticals, SK pharmteco, Roquette, Aptar and Schott Pharma.
Chemicals/Chemical API Manufacturing
* Xellia Plans Multi-Year Phase-out of Antibiotic API Mfg In Denmark
Biologics Manufacturing
* SK pharmteco Opens Plasmid Suite for Cell & Gene Therapies
Formulation Development/Drug Product Manufacturing
* Roquette Reorganizes into Two Business Groups Following IFF Pharma Acquisition
Packaging
* Aptar Launches Clinical-Scale Solid Dosage Packaging Facility
* Schott Agrees To Sell a 35% Stake in Indian JV
Chemicals/Chemical API Manufacturing
Xellia Plans Multi-Year Phase-out of Antibiotic API Mfg In Denmark
Xellia Pharmaceuticals, a provider of fermented and semi-synthetic small molecule based products and finished dosage forms, has announced plans for a gradual closure and transition of its manufacturing operations for anti-infective active pharmaceutical ingredients (APIs) in Copenhagen, Denmark, to facilities outside of Denmark. The phased migration of the company’s anti-infective products will take place over eight to 10 years culminating in the eventual retirement of its Copenhagen manufacturing site.
The company says that its planned operational transition out of its Copenhagen facility “reflects Xellia Pharmaceuticals’ ongoing efforts to address the challenges of intense price pressure, rising operational expenses, and inherent market dynamics within the anti-infectives sector,” said the company in a May 6, 2025, release. “The company is now transforming its setup significantly to enhance long-term manufacturing sustainability and supply chain resilience. Several potential locations within and beyond the organization’s current manufacturing network are being evaluated as part of the transition.”
A transfer of the antibiotic API, vancomycin hydrochloride, out of the company’s Copenhagen site to other manufacturing facilities within its network will initialize the phasing of supply chain adjustments. This is set to be completed in the course of 2028. A geographic scenario detailing the remaining products manufactured in Copenhagen is underway, according to the company.
Source: Xellia Pharmaceuticals
Biologics Manufacturing
SK pharmteco Opens Plasmid Suite for Cell & Gene Therapies
SK pharmteco, a CDMO of small-molecule active pharmaceutical ingredients (APIs) and cell and gene therapies, has opened a new cGMP plasmid suite at its facility in King of Prussia, Pennsylvania. Plasmids are a component of cell and gene therapies.
Overall, SK pharmteco’s 300,000-square-foot King of Prussia facility provides process development and plasmid manufacturing with four dedicated suites capable of producing three distinct plasmid grades. Additionally, the site features two independent aseptic fill–finish operations, contract analytical testing services, and an in-house cGMP cell line.
Separately, the company announced the launch of a new proprietary plasmid engineering platform, Plasmid-IQ Design, designed to optimize genetic constructs and enhance their performance, stability, and production efficiency.
Source: SK pharmteco (facility) and SK pharmteco (platform)
Formulation Development/Drug Product Manufacturing
Roquette Reorganizes into Two Business Groups Following IFF Pharma Acquisition
Roquette, a manufacturer of excipients and plant-based ingredients, has announced a new organization following its acquisition of IFF Pharma Solutions, a provider of excipients, which was completed earlier this month (May 2025). The new structure went into effect May 1, 2025, and features two business groups: (1) the Health & Pharma Solutions Business Group and (2) the Nutrition & Bioindustry Business Group.
Isabelle Bouvier, formerly Chief Financial Officer (CFO), Roquette, was named as CEO of the Health & Pharma Solutions Business Group. Béatrice Totel, formerly Head of Business Finance, Roquette, now takes the role of CFO. Pascal Leroy, who has held various leadership positions in Roquette overseeing Commercial, Procurement, Quality and Supply Chain activities, was named as CEO of the Nutrition & Bioindustry Business Group.
With the acquisition of IFF Pharma Solutions, Roquette now has more than 11,000 employees and 40 manufacturing sites.
Source: Roquette
Packaging
Aptar Launches Clinical-Scale Solid Dosage Packaging Facility
Aptar CSP Technologies, part of AptarGroup, a provider of drug-delivery systems, consumer product dispensing, and active material science products and services, has launched a GMP manufacturing facility in New Jersey to support clinical packaging for oral solid dose and capsule-based dry-powder inhalers using Aptar CSP’s proprietary Activ-Polymer platform and Activ-Blister technology.
Aptar CSP’s Activ-Blister technology integrates an engineered active film material into thermoform and cold-form blister packaging configurations to create a microclimate that protects individual doses from moisture, oxygen, volatile organic compounds, and degradation, including reducing the risk of N-nitrosamine formation, according to the company.
The new site, which is the result of a collaboration with MOD3 Pharma, a contract provider of drug-delivery services, will offer R&D support, Phase I and II clinical material manufacturing, a full CMC package (chemistry, manufacturing, and controls), stability studies, and clinical supply management.
Source: Aptar CSP Technologies
Schott Agrees To Sell a 35% Stake in India JV
Schott Pharma, a pharmaceutical packaging company, has announced that TPG, an asset management firm, has entered into a binding agreement to acquire a 35% stake in Schott Poonawalla, its joint venture with the Serum Institute of India (SII), a vaccine manufacturer.
Schott Poonawalla is a joint venture of Schott Pharma and SII, part of the Cyrus Poonawalla Group. TPG Growth, TPG’s middle-market and growth equity platform, is funding the investment, along with Novo Holdings as a co-investor. Following the transaction, SII will retain a minority stake in the joint venture, and Schott Pharma will maintain 50% ownership.
The transaction is subject to customary closing conditions and is expected to close within the first half of 2025.
Source: Schott Pharma
